Lebanon vs Naoero: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Lebanon
67.0%
in 2025
Naoero
66.0%
in 2025
Lebanon rank
137th
Naoero rank
138th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Lebanon
- Naoero
How they compare
Lebanon currently reports 67.0% against 66.0% in Naoero, a difference of 1.0%.
The two have swapped places 3 times across 18 shared years of data; in 2008 it was Naoero ahead.
Lebanon ranks 137th and Naoero ranks 138th of 194 countries.
Lebanon has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Lebanon | Naoero | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 24.6% | 0.0% | 24.6% | Lebanon |
| 2020s | 68.2% | 62.7% | 5.5% | Lebanon |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Lebanon or Naoero?
- Lebanon, at 67.0% against 66.0% in Naoero as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Lebanon and Naoero?
- 1.0%, with Lebanon ahead.
- How many years of comparable data are there for Lebanon and Naoero?
- 18 years are reported by both, from 2008 to 2025.
- How do Lebanon and Naoero rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Lebanon ranks 137th and Naoero ranks 138th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.